Akoya Biosciences, Inc.

NasdaqGS:AKYA Stock Report

Market Cap: US$142.1m

Akoya Biosciences Management

Management criteria checks 3/4

Akoya Biosciences' CEO is Brian McKelligon, appointed in Jul 2017, has a tenure of 7.25 years. total yearly compensation is $2.92M, comprised of 18.6% salary and 81.4% bonuses, including company stock and options. directly owns 0.075% of the company’s shares, worth $106.86K. The average tenure of the management team and the board of directors is 3.3 years and 4.2 years respectively.

Key information

Brian McKelligon

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage18.6%
CEO tenure7.3yrs
CEO ownership0.08%
Management average tenure3.3yrs
Board average tenure4.2yrs

Recent management updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Recent updates

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

CEO Compensation Analysis

How has Brian McKelligon's remuneration changed compared to Akoya Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$68m

Dec 31 2023US$3mUS$543k

-US$63m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$76m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$3mUS$518k

-US$71m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$2mUS$393k

-US$44m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$516kUS$350k

-US$22m

Dec 31 2019US$484kUS$333k

-US$18m

Compensation vs Market: Brian's total compensation ($USD2.92M) is above average for companies of similar size in the US market ($USD650.91K).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.


CEO

Brian McKelligon (55 yo)

7.3yrs

Tenure

US$2,919,599

Compensation

Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...


Leadership Team

NamePositionTenureCompensationOwnership
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 106.9k
John Ek
CFO, Principal Financial Officer & Principal Accounting Officer1.6yrsUS$2.37m0.092%
$ 131.2k
Frederic Pla
Chief Operating Officer3.6yrsUS$1.21m0.061%
$ 86.8k
Priyam Shah
Senior Director of Business Development & Investor Relations Strategyno datano datano data
Jennifer Kamocsay
General Counsel1.7yrsno data0.012%
$ 17.5k
Niro Ramachandran
Chief Business Officer4.2yrsUS$365.22k0.29%
$ 415.6k
Pascal Bamford
Senior Vice President3yrsno data0.17%
$ 237.5k
Rob Hart
Secretaryno datano datano data

3.3yrs

Average Tenure

53yo

Average Age

Experienced Management: AKYA's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 106.9k
Robert Shepler
Independent Director8.9yrsUS$251.66k0.75%
$ 1.1m
Myla Lai-Goldman
Independent Director3.1yrsUS$237.50k0.040%
$ 57.4k
Thomas Schnettler
Independent Director5.1yrsUS$220.00k0%
$ 0
Thomas Raffin
Director8.9yrsUS$210.00k0.47%
$ 673.3k
Matthew Winkler
Independent Director7.3yrsUS$232.50k1.99%
$ 2.8m
James Allison
Member of Scientific Advisory Boardless than a yearno datano data
Scott Mendel
Independent Chairman3.3yrsUS$250.00k0.058%
$ 81.8k
Padmanee Sharma
Member of Scientific Advisory Boardless than a yearno datano data
Garry Nolan
Chair of the Scientific Advisory Boardless than a yearUS$220.00k1.25%
$ 1.8m

4.2yrs

Average Tenure

66yo

Average Age

Experienced Board: AKYA's board of directors are considered experienced (4.2 years average tenure).